HRP20160399T1 - Sulfonamidi, namijenjeni sprječavanju dijabetesa - Google Patents

Sulfonamidi, namijenjeni sprječavanju dijabetesa Download PDF

Info

Publication number
HRP20160399T1
HRP20160399T1 HRP20160399TT HRP20160399T HRP20160399T1 HR P20160399 T1 HRP20160399 T1 HR P20160399T1 HR P20160399T T HRP20160399T T HR P20160399TT HR P20160399 T HRP20160399 T HR P20160399T HR P20160399 T1 HRP20160399 T1 HR P20160399T1
Authority
HR
Croatia
Prior art keywords
diabetes
prevention
compound
sulfonamides
trifluoromethanesulfonyloxy
Prior art date
Application number
HRP20160399TT
Other languages
English (en)
Croatian (hr)
Inventor
Lorenzo Piemonti
Luisa Daffonchio
Marcello Allegretti
Original Assignee
Dompé Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompé Farmaceutici S.P.A. filed Critical Dompé Farmaceutici S.P.A.
Publication of HRP20160399T1 publication Critical patent/HRP20160399T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51Y being a hydrogen or a carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HRP20160399TT 2009-10-06 2010-10-06 Sulfonamidi, namijenjeni sprječavanju dijabetesa HRP20160399T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09172365A EP2308485A1 (en) 2009-10-06 2009-10-06 Sulfonamides for the prevention of diabetes
PCT/EP2010/064920 WO2011042465A1 (en) 2009-10-06 2010-10-06 Sulfonamides for the prevention of diabetes
EP10768898.8A EP2485724B1 (en) 2009-10-06 2010-10-06 Sulfonamides for the prevention of diabetes

Publications (1)

Publication Number Publication Date
HRP20160399T1 true HRP20160399T1 (hr) 2016-05-20

Family

ID=41716341

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160399TT HRP20160399T1 (hr) 2009-10-06 2010-10-06 Sulfonamidi, namijenjeni sprječavanju dijabetesa

Country Status (24)

Country Link
US (2) US8846755B2 (enExample)
EP (2) EP2308485A1 (enExample)
JP (1) JP5745526B2 (enExample)
KR (1) KR101737656B1 (enExample)
CN (1) CN102639128B (enExample)
AU (1) AU2010305384B2 (enExample)
BR (1) BR112012007989B1 (enExample)
CA (1) CA2776021C (enExample)
CY (1) CY1117599T1 (enExample)
DK (1) DK2485724T3 (enExample)
EA (1) EA021788B1 (enExample)
ES (1) ES2570463T3 (enExample)
HR (1) HRP20160399T1 (enExample)
HU (1) HUE028132T2 (enExample)
IL (1) IL219038A (enExample)
ME (1) ME02385B (enExample)
MX (1) MX2012004087A (enExample)
NZ (1) NZ599171A (enExample)
PL (1) PL2485724T3 (enExample)
RS (1) RS54693B1 (enExample)
SI (1) SI2485724T1 (enExample)
SM (1) SMT201600126B (enExample)
WO (1) WO2011042465A1 (enExample)
ZA (1) ZA201202462B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
EP3281937A1 (en) * 2016-08-09 2018-02-14 Dompé farmaceutici S.p.A. Sulfonamides as gpr40- and gpr120-agonists
CN109890364B (zh) 2016-10-03 2023-10-17 儿童医疗中心公司 糖尿病肾病的预防和治疗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
ITMI20010206A1 (it) 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
US20040242498A1 (en) * 2003-02-27 2004-12-02 Collins Tassie L. CXCR3 antagonists
PT1776336E (pt) 2004-03-23 2009-12-18 Dompe Spa Derivados de ácido 2-fenilpropiónico e composições farmacêuticas que os contêm
EP1579859B1 (en) 2004-03-25 2006-12-13 DOMPE' pha.r.ma s.p.a. Use of N-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury
WO2009117706A2 (en) * 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treatment using anti-mif antibodies
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets

Also Published As

Publication number Publication date
KR101737656B1 (ko) 2017-05-18
EP2485724B1 (en) 2016-02-10
SMT201600126B (it) 2016-07-01
US9556115B2 (en) 2017-01-31
US20130059908A1 (en) 2013-03-07
NZ599171A (en) 2014-03-28
HUE028132T2 (en) 2016-11-28
BR112012007989B1 (pt) 2019-10-22
US8846755B2 (en) 2014-09-30
EA021788B1 (ru) 2015-08-31
US20150011639A1 (en) 2015-01-08
AU2010305384A1 (en) 2012-04-26
DK2485724T3 (en) 2016-05-02
ZA201202462B (en) 2013-06-26
CA2776021A1 (en) 2011-04-14
ME02385B (me) 2016-09-20
WO2011042465A1 (en) 2011-04-14
CA2776021C (en) 2017-08-01
CN102639128A (zh) 2012-08-15
ES2570463T3 (es) 2016-05-18
EA201270512A1 (ru) 2012-11-30
RS54693B1 (sr) 2016-08-31
CY1117599T1 (el) 2017-04-26
EP2308485A1 (en) 2011-04-13
IL219038A0 (en) 2012-06-28
CN102639128B (zh) 2014-02-26
EP2485724A1 (en) 2012-08-15
PL2485724T3 (pl) 2016-07-29
HK1174557A1 (en) 2013-06-14
SI2485724T1 (sl) 2018-12-31
KR20120083889A (ko) 2012-07-26
JP5745526B2 (ja) 2015-07-08
JP2013506703A (ja) 2013-02-28
AU2010305384B2 (en) 2016-02-04
IL219038A (en) 2015-07-30
MX2012004087A (es) 2012-08-23

Similar Documents

Publication Publication Date Title
NZ607794A (en) N-acylsulfonamide apoptosis promoters
EA201201378A1 (ru) Определенные аминопиримидины, композиции на их основе и способы их использования
ZA201009079B (en) "sulfonamide compounds or salts thereof"
HRP20160399T1 (hr) Sulfonamidi, namijenjeni sprječavanju dijabetesa
HRP20120323T1 (en) Diarylhydantoin compounds
EA201691119A1 (ru) Производные мочевины или их фармакологически приемлемые соли
NZ603198A (en) Novel hydroxamic acid derivative
MY165918A (en) Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
UA112317C2 (uk) Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину
WO2014068402A3 (en) Pharmaceutical formulation containing thienotriazolodiazepine compounds
AR057894A1 (es) Derivados de tiofeno
MX2009011579A (es) Pirimidinonas como moduladores de caseina cinasa ii (ck2).
HRP20211682T1 (hr) 2-(2,4,5-supstituirani-anilino) pirimidinski spojevi
HRP20110841T1 (hr) Korisni monobaktamski antibiotici
HRP20160283T1 (hr) Farmaceutski pripravak koji sadrži derivat kinolina
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
UA116923C2 (uk) (6S,9aS)-N-БЕНЗИЛ-6-[(4-ГІДРОКСИФЕНІЛ)МЕТИЛ]-4,7-ДІОКСО-8-({6-[3-(ПІПЕРАЗИН-1-ІЛ)АЗЕТИДИН-1-ІЛ]ПІРИДИН-2-ІЛ}МЕТИЛ)-2-(ПРОП-2-ЕН-1-ІЛ)-ОКТАГІДРО-1H-ПІРАЗИНО[2,1-c][1,2,4]ТРИАЗИН-1-КАРБОКСАМІДНА СПОЛУКА
NZ596431A (en) Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
BRPI0814957B8 (pt) composto, agente farmacêutico, e, uso do composto
HK1201833A1 (en) Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one
HRP20160291T1 (hr) Soli od n-hidroksi-3-(4-(((2-(2-metil-1h-indol-3-il)etil)amino)metil)fenil)-2e-2-propenamida
HRP20171058T1 (hr) Derivati dipeptida lizinske glutaminske kiseline
BR112014027859A2 (pt) composição detergente para lavagem de roupas compreedendo uma partícula que tem um agente de tonalização e argila
HRP20120957T1 (hr) Stabilni farmaceutski sastav koji sadrži pirimidin-sulfamid
EA201101301A1 (ru) Натриевая соль 5-циклопропил-2-{[2-(2,6-дифторфенил)пиримидин-5-ил]амино}бензойной кислоты в качестве ингибиторов dhodh